Skip to main content

Pressure BioSciences Targets $2M in Private Placement

NEW YORK (GenomeWeb News) – Pressure BioSciences has raised around $1.7 million through a private placement of units, the firm disclosed today in a filing with the US Securities and Exchange Commission.

The company said that it sold 4,257 units at a price of $400 per unit. The $1.7 million it raised is the first tranche of a targeted $2 million, said Pressure Bio, adding that it expects to close one or more tranches on or before Feb. 28, 2013.

Each unit purchased in the initial tranche consists of one share of newly created Series J Convertible Preferred Stock, which is convertible into 1,000 shares of the firm's common stock, and a warrant to purchase 1,000 shares of common stock at an exercise price equal to $.40 per share, with a term expiring on Feb. 6, 2016.

Of the initial $1.7 million Pressure Bio received, $590,000 came in the form of cash and $1.1 million came from the conversion of outstanding indebtedness and accrued board of directors' fees. The purchasers in the initial tranche consisted of existing and new investors in the firm, as well as members of Pressure Bio's board of directors.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.